Iovance Biotherapeutics Inc (IOVA) Expected to Announce Earnings of -$0.34 Per Share

Wall Street brokerages expect that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will report earnings per share of ($0.34) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.36). Iovance Biotherapeutics reported earnings of ($0.31) per share in the same quarter last year, which would indicate a negative year over year growth rate of 9.7%. The firm is scheduled to announce its next earnings report on Tuesday, October 30th.

According to Zacks, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($1.24). For the next year, analysts anticipate that the firm will post earnings of ($1.43) per share, with EPS estimates ranging from ($1.62) to ($1.24). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.02).

IOVA has been the topic of several research reports. Zacks Investment Research lowered shares of Iovance Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 12th. HC Wainwright set a $22.00 price objective on shares of Iovance Biotherapeutics and gave the stock a “buy” rating in a research note on Thursday, September 6th. Chardan Capital reissued a “buy” rating and set a $30.00 price objective on shares of Iovance Biotherapeutics in a research note on Friday, July 6th. BidaskClub raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 27th. Finally, Citigroup reissued an “outperform” rating and set a $25.00 price objective (up previously from $22.00) on shares of Iovance Biotherapeutics in a research note on Friday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $23.39.

NASDAQ:IOVA opened at $11.93 on Friday. Iovance Biotherapeutics has a one year low of $6.60 and a one year high of $19.90. The stock has a market cap of $1.08 billion, a P/E ratio of -8.46 and a beta of 2.72.

A number of large investors have recently bought and sold shares of the stock. Northern Trust Corp boosted its stake in Iovance Biotherapeutics by 16.9% during the second quarter. Northern Trust Corp now owns 1,018,949 shares of the biotechnology company’s stock worth $13,043,000 after acquiring an additional 146,964 shares in the last quarter. California Public Employees Retirement System lifted its stake in shares of Iovance Biotherapeutics by 5.6% in the second quarter. California Public Employees Retirement System now owns 105,440 shares of the biotechnology company’s stock worth $1,350,000 after buying an additional 5,598 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Iovance Biotherapeutics by 39.7% in the second quarter. Millennium Management LLC now owns 712,922 shares of the biotechnology company’s stock worth $9,125,000 after buying an additional 202,558 shares in the last quarter. RA Capital Management LLC lifted its stake in shares of Iovance Biotherapeutics by 70.1% in the second quarter. RA Capital Management LLC now owns 1,121,153 shares of the biotechnology company’s stock worth $14,351,000 after buying an additional 462,094 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Iovance Biotherapeutics by 242.5% in the second quarter. Bank of America Corp DE now owns 161,657 shares of the biotechnology company’s stock worth $2,070,000 after buying an additional 114,459 shares in the last quarter. 87.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Further Reading: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply